GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT07221214
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Alcohol
  • Cardiovascular Disease Prevention
  • HIV
  • Smoking Cigarette

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are: 1. Does semaglutide lower the average number of alcoholic beverages participants drink per week? 2. Does semaglutide lower the average number of cigarettes participants smoke per day? 3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco? Researchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week. Participants will: 1. Take semaglutide for 3 months 2. Visit the research clinic 3 times for checkups and tests 3. Provide blood samples, stool samples, and saliva samples for tests.

Key Dates

First listed
Oct 27, 2025
Start date
Apr 17, 2026
Status verified
May 2026
Primary completion
Oct 31, 2029
Completion
Jan 31, 2030

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    drug intervention
  • Placebo Comparator: Placebo

Primary Outcome Measure

Average drinks/week past 30 days at 3 months [ Time Frame: 3 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37232
Rachel Jones, MS
[email protected]
615-421-3508

Find similar trials in Nashville, TN

Nationwide
HIV trialsInfectious disease trials
By condition
HIV
By specialty
Infectious disease
By research site
Vanderbilt University Medical Center· Nashville, TN

Related Studies